2 completed, 2 not yet recruiting, 2 recruiting, 1 unknown. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Not yet recruiting 2, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow BEBT-908: new trials by email Literature Review of BEBT-908 trials Research Report on BEBT-908
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Ifupinostat Hydrochloride - B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 15 | 2026-09-01 | 2026-10-02 |
| A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection - Previously Untreated Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | BeBetter Med Inc | 120 | 2026-07-01 | 2026-06-30 |
| BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients BEBT-908, Cyclophosphamide, Vincristine - Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | Ruijin Hospital | 23 | 2025-12-15 | 2025-12-24 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Unknown | BeBetter Med Inc | 75 | 2023-12-01 | 2023-12-11 |
| Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects BEBT-908 for injection - Relapsed or Refractory Diffuse Large B-cell Lymphoma | Phase 2 | Completed | BeBetter Med Inc | 128 | 2020-06-12 | 2026-08-18 |
| Study of BEBT-908 in Subjects With Advanced Hematological Tumors BEBT-908 for injection - Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | BeBetter Med Inc | 32 | 2016-03-02 | 2023-10-13 |
Lymphoma, Large B-Cell, Diffuse (3) · Recurrence (2) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasm, Residual (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
BeBetter Med Inc (5) · Ruijin Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (7)
Yuankai Shi, Phd (3) · Hui Zhou, Phd (1)